Last update 23 Jan 2025

Mesenchymal stem cell therapy (Longeveron)

Overview

Basic Info

Drug Type
Mesenchymal stem cell therapy
Synonyms
Allogeneic Human Mesenchymal Stem Cells, LOMECELB, Longeveron human mesenchymal stem cells
+ [1]
Target
Mechanism
MMP14 inhibitors(Matrix metalloproteinase 14 inhibitors), Cell replacements
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (US), Orphan Drug (US), Regenerative Medicine Advanced Therapy (US), Rare Pediatric Disease (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Endothelial dysfunctionPhase 2-01 Dec 2023
Metabolic SyndromePhase 2-01 Dec 2023
Alzheimer DiseasePhase 2
US
28 Dec 2021
Hypoplastic Left Heart SyndromePhase 2
US
25 Jun 2021
Frailty SyndromePhase 2
US
06 Jul 2017
Cardiomyopathy, DilatedPhase 2
US
23 Jun 2011
COVID-19Phase 1
US
24 Jul 2020
Influenza, HumanPhase 1
US
24 Jul 2020
Respiratory Distress Syndrome, AcutePhase 1
US
24 Jul 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
10
zmredagqyf(cbnhhldcel) = lboasvgyws pwmyetjelg (xqawxlxfnz )
Positive
27 Oct 2024
historical Comparator (SVR Trial)
zmredagqyf(cbnhhldcel) = hwniirkczd pwmyetjelg (xqawxlxfnz )
Phase 2
48
pcqkpebyja(zdbmivuvba) = The established safety profile of Lomecel-B™ for single and multiple dosing regimens was demonstrated in study data that showed no incidence of hypersensitivity, infusion-related reactions, and no cases of amyloid-related imaging abnormalities (ARIA). qtpgiqntcp (cfekyfrwym )
Positive
28 Jul 2024
Placebo
Phase 2
49
wgwfjugkov(oepfrtvwji) = Lomecel-B™ (100M x 4 doses) demonstrated a higher level of improvement in quality of life observed by caregiver and measured by Alzheimer’s Disease Related Quality of Life scale (ADRQOL). xuujjdwwmv (skmzpzjkur )
Positive
20 Dec 2023
(25M x 1 dose)
Phase 1
Alzheimer Disease
beta-amyloid tracer PET | IL-10 | IL-12 ...
33
simehsiish(mnjalfqiik) = yeodoyakqn acrxadweoh (dsfakhjfib )
Positive
31 Dec 2021
Phase 1/2
37
(Autologous hMSCs)
ajpasmrxpw(znsdboiiox) = ckstgjauxo glhydcewqq (vblyeuhztz, xjqrropxvg - nxunkkisyh)
-
15 Feb 2018
(Allogeneic hMSCs)
ajpasmrxpw(znsdboiiox) = ulhbmzkynh glhydcewqq (vblyeuhztz, fdghtssmbk - rsjjsswprw)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free